Drugs / Quinquina-Stevia
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04501965 | Jun → Aug 2020 | COVID-19 | Institute for Research and Development of Medicinal and Food Plants of Guinea | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quinquina-Stevia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04501965 ↗ |
| Known as | Cinchona | “It is Cinchona, an antimalarial and a combination of 4 plants with antiviral, antimalarial, antitussive and anti-inflammatory properties” NCT04501965 ↗ |
| Route | Oral | “Patients receive 3.5g tea bags of Cinchona/Stevia powder orally at the rate of 3 tea bags per day for 10 days” NCT04501965 ↗ |